as of 13:29 on December 28, 2023, the national security biomedical index (399441) rose 2.22 percent, the constituent stock aimei ke (300896) rose 11.69 percent, huaxi biology (688363) rose 7.25 percent, medissi (688202) rose 6.80 percent, Tiger medicine (300347), zhaoyan new drug (603127) and other stocks followed. Biopharmaceutical ETF Fund (159508) rose 2.16 percent to its latest price of $1. Over a long period of time, the fund has "absorbed" 42.3032 million yuan in total in the past five trading days.

At the valuation level, the latest price-to-earnings ratio (PE-TTM) of the National Securities Biopharmaceutical Index tracked by the Biopharmaceutical ETF is only 24.63 times, at a fraction of 15.36 per cent in the last three years, I .e., the valuation is below 84.64 per cent in the last three years and at an all-time low.

The Biopharmaceutical ETF closely tracks the China Securities Biopharmaceutical Index. In order to reflect the overall performance of listed companies related to the biomedical industry in the Shanghai and Shenzhen markets, it provides investors with richer indexed investment targets, promotes the development of index fund products, and compiles the China Securities Biopharmaceutical Index.

The data shows that as of November 30, 2023, the top ten heavyweights in the National Securities Biomedical Index (399441) are Yao Ming Kant (603259), Zhifei Biology (300122), Changchun Hi-tech (000661), Watson Biology (300142), Shanghai Les (002252), Fosun Medicine (600196), Tiger Medicine (300347), Kelaiying (002821), Kang Longhuacheng (300759) and Tiantan Biology (600161), with the top ten heavyweights accounting for 64.92.

Societe Generale Securities believes that the current pharmaceutical sector both offensive and defensive, with the recent plate volatility valuation cost performance to further improve, continue to be optimistic about 2024 investment opportunities and innovation main line direction, focus on innovative drugs, innovative equipment, CXO and other tracks. On the policy side, the current policy framework is more stable and the industry impact continues to moderate marginally. Near the end of the year plate policy into the intensive landing period, the recent drug field of innovative drug negotiation results, the field of equipment artificial crystal collection results, Anhui IVD reagent collection program and other policies, the overall results are more in line with expectations.

biomedical ETF fund (159508), over-the-counter link (class a: 012598; Class C: 012599).